Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Entecavir (Bristol-Myers Squibb).

A Billich1

  • 1Novartis Research Institute, General Dermatology, Vienna, Austria. andreas.billich@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
PubMed
Summary

Entecavir is a potent antiviral drug developed for hepatitis B virus (HBV) infection. It inhibits viral DNA polymerase, showing high efficacy and low toxicity in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GS-4104 Gilead Sciences Inc.

IDrugs : the investigational drugs journal·2008
Same author

Amprenavir (Vertex Pharmaceuticals Inc).

IDrugs : the investigational drugs journal·2005
Same author

Steroid sulfatase in the human hair follicle concentrates in the dermal papilla.

The Journal of investigative dermatology·2002
Same author

AIDSVAX. VaxGen.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.

European journal of medicinal chemistry·2001
Same author

Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.

Journal of immunology (Baltimore, Md. : 1950)·2001

Area of Science:

  • Virology
  • Hepatology
  • Pharmacology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Current treatments for HBV infection have limitations, necessitating the development of novel antiviral agents.
  • Entecavir, a cyclopentyl guanosine analog, was initially investigated for herpes simplex virus infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of entecavir for the treatment of hepatitis B virus (HBV) infection.
  • To characterize the mechanism of action of entecavir as a viral replication inhibitor.

Main Methods:

  • Entecavir's antiviral activity was assessed by measuring its inhibitory concentration (ED50) against HBV.
  • Cytotoxicity was evaluated by determining the 50% cytotoxic concentration (CC50).
  • The mechanism of action was investigated through its effect on HBV DNA polymerase.

Main Results:

  • Entecavir demonstrated potent inhibition of HBV replication with an ED50 of 3.0 nM, significantly lower than lamivudine (200 nM).
  • The compound exhibited low toxicity, with a CC50 of 30,000 nM.
  • Entecavir acts by inhibiting HBV DNA polymerase, with its triphosphate form being a potent inhibitor in preclinical models.

Conclusions:

  • Entecavir is a highly potent and selective inhibitor of HBV replication.
  • Its favorable efficacy and safety profile support its continued development for HBV treatment.
  • Clinical trials are underway to further establish entecavir's therapeutic value in patients with HBV infection.

Related Experiment Videos